Mesoblast保证了160万元 用于推出新的儿科移植 - 反向 - 宿主疾病药物,Ryoncil。 Mesoblast secures $160M to launch new pediatric graft-versus-host disease drug, Ryoncil®.

Mesoblast Limited是治疗煽动性疾病的细胞药物的领头人,它已经获得1.6亿美元的资金,用于支持美国在2025年Q1末推出Ryoncilí。 Mesoblast Limited, a leader in cellular medicines for inflammatory diseases, has secured $160 million in financing to support the U.S. launch of Ryoncil® by the end of Q1 2025. Ryoncil经林业发展局于2024年12月批准,是治疗患有类固醇-抗逆转录血性急性移植-负鼠-宿主疾病的儿童的第一个疗法。 Ryoncil®, approved by the FDA in December 2024, is the first therapy for children with steroid-refractory acute graft-versus-host disease. 该公司正准备通过销售网络进行商业发射,目的是解决价值超过10亿美元的市场问题。 The company is preparing for commercial launch with a distribution network and aims to address a market valued over $1 billion.